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Myriocin-mediated up-regulation of hepatocyte apoA-I synthesis is associated
with ERK inhibition
Abstract
Sphingolipids including sphingomyelin have been implicated as potential atherogenic lipids. Studies in
apoE (apolipoprotein E)-null mice have revealed that the serine palmitoyltransferase inhibitor myriocin
reduces plasma levels of sphingomyelin, ceramide, sphingosine-I-phosphate and glycosphingolipids and
that this is associated with potent inhibition of atherosclerosis. Interestingly, hepatic apoA-I
(apolipoprotein A-I) synthesis and plasma HDL (high-density lipoprotein)cholesterol levels were also
increased in apoE-null mice treated with myriocin. Since myriocin is a known inhibitor of ERK
(extracellular-signal-related kinase) phosphorylation, we assessed the possibility that myriocin may be
acting to increase hepatic apoA-I production via this pathway. To address this, HepG2 cells and primary
mouse hepatocytes were treated with 200 mu M myriocin for up to 48 h. Myriocin increased apoA-I mRNA
and protein levels by approx. 3- and 2-fold respectively. Myriocin also increased apoA-I secretion up to
3.5-fold and decreased ERK phosphorylation by approx. 70%. Similar findings were obtained when primary
hepatocytes were isolated from apoE-null mice that were treated with myriocin (intraperitoneal injection
at a dose of 0.3 mg/kg body weight). Further experiments revealed that the MEK (mitogen-activated
protein kinase/ERK kinase) inhibitor PD98059 potently inhibited ERK phosphorylation, as expected, and
increased primary hepatocyte apoA-I production by 3-fold. These results indicate that ERK
phosphorylation plays a role in regulating hepatic apoA-I expression and suggest that the anti-atherogenic
mechanism of action for myriocin may be linked to this pathway.

Keywords
associated, myriocin, mediated, erk, up, inhibition, regulation, hepatocyte, apoa, i, synthesis, CMMB

Disciplines
Life Sciences | Physical Sciences and Mathematics | Social and Behavioral Sciences

Publication Details
Glaros, E. N., Kim, W. & Garner, B. (2010). Myriocin-mediated up-regulation of hepatocyte apoA-I synthesis
is associated with ERK inhibition. Clinical Science, 118 (11-12), 727-736.

This journal article is available at Research Online: https://ro.uow.edu.au/scipapers/530

www.clinsci.org
Clinical Science (2010) 118, 727–736 (Printed in Great Britain) doi:10.1042/CS20090452

727

Myriocin-mediated up-regulation of hepatocyte
apoA-I synthesis is associated with ERK
inhibition
Elias N. GLAROS∗ †, Woojin S. KIM∗ † and Brett GARNER∗ †‡
Prince of Wales Medical Research Institute, Sydney, NSW 2031, Australia, †School of Medical Sciences, Faculty of Medicine,
University of New South Wales, Sydney, NSW 2052, Australia, and ‡School of Biological Sciences, University of Wollongong,
Wollongong, NSW 2522, Australia

A

B

S

T

R

A

C

T

Sphingolipids including sphingomyelin have been implicated as potential atherogenic lipids.
Studies in apoE (apolipoprotein E)-null mice have revealed that the serine palmitoyltransferase
inhibitor myriocin reduces plasma levels of sphingomyelin, ceramide, sphingosine-1-phosphate and
glycosphingolipids and that this is associated with potent inhibition of atherosclerosis. Interestingly,
hepatic apoA-I (apolipoprotein A-I) synthesis and plasma HDL (high-density lipoprotein)cholesterol levels were also increased in apoE-null mice treated with myriocin. Since myriocin
is a known inhibitor of ERK (extracellular-signal-related kinase) phosphorylation, we assessed the
possibility that myriocin may be acting to increase hepatic apoA-I production via this pathway. To
address this, HepG2 cells and primary mouse hepatocytes were treated with 200 μM myriocin
for up to 48 h. Myriocin increased apoA-I mRNA and protein levels by approx. 3- and 2fold respectively. Myriocin also increased apoA-I secretion up to 3.5-fold and decreased ERK
phosphorylation by approx. 70 %. Similar findings were obtained when primary hepatocytes
were isolated from apoE-null mice that were treated with myriocin (intraperitoneal injection
at a dose of 0.3 mg/kg body weight). Further experiments revealed that the MEK (mitogenactivated protein kinase/ERK kinase) inhibitor PD98059 potently inhibited ERK phosphorylation,
as expected, and increased primary hepatocyte apoA-I production by 3-fold. These results indicate
that ERK phosphorylation plays a role in regulating hepatic apoA-I expression and suggest that the
anti-atherogenic mechanism of action for myriocin may be linked to this pathway.

INTRODUCTION
Atherosclerosis is a major cause of CVD (cardiovascular
disease) and accounts for approx. 50 % of all deaths
in westernized countries [1]. Hypercholesterolaemia is
a major risk factor for atherosclerosis, and it is clear
that HMG-CoA (3-hydroxy-3-methylglutaryl-CoA)

reductase inhibitors (statins) effectively lower serum
total cholesterol and LDL (low-density lipoprotein)cholesterol levels and reduce cardiovascular morbidity
and mortality [2]. However, it is recognized that a
significant number of patients are either resistant to
or intolerant to statins, and with guidelines for LDLcholesterol levels to be reduced below 2 mM, it has

Key words: apolipoprotein A-I (apoA-I), atherosclerosis, extracellular-signal regulated kinase (ERK), hepatocyte, myriocin,
sphingolipid.
Abbreviations: 4-AAP, 4-aminoantipyrine; apoA-I, apolipoprotein A-I; apoE, apolipoprotein-E; DAOS, N-ethyl-N-(2-hydroxy3-sulfopropyl)-3,5-dimethoxyaniline sodium salt; DMEM, Dulbecco’s modified Eagle’s medium; ERK, extracellular-signal-related
kinase; FCS, fetal calf serum; GCS, glucosylceramide synthase; GSL, glycosphingolipid; HDL, high-density lipoprotein; HRP,
horseradish peroxidase; i.p., intraperitoneal(ly); LDL, low-density lipoprotein; MAPK, mitogen-activated protein kinase; MEK,
MAPK/ERK kinase; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide; qPCR, quantitative PCR; S1P,
sphingosine 1-phosphate; SM, sphingomyelin; SMase, sphingomyelinase; SPT, serine palmitoyltransferase.
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been reported that less than 50 % of patients treated
with statins achieve their targets [3]. In order to
address this problem, statin combination therapies are
under investigation; for example, using the cholesterol
absorption inhibitor ezetimibe [3]. We predict that, as
an adjunct to statin therapy, approaches targeting proatherogenic pathways that are not primarily aimed at
reducing cholesterol synthesis or absorption would result
in a two-pronged approach to treat atherosclerosis.
Therapeutic targeting of the sphingolipid biosynthetic
pathway may represent a feasible approach to treat
atherosclerosis [4–7]. Previous studies have shown
that plasma SM (sphingomyelin) concentration is an
independent risk factor for coronary artery disease [8].
SM is also known to accumulate in atherosclerotic
lesions in humans and animal models [9,10]. Similar
relationships have been established with plasma GSLs
(glycosphingolipids). GSLs are elevated in patients at
increased risk of developing atherosclerosis [11], and
these sphingolipids accumulate in atherosclerotic lesions
in humans and in apoE (apolipoprotein E)−/− mice
[12,13]. In addition, several in vitro studies have revealed
potential atherogenic properties for specific GSLs. These
include the findings that LacCer (lactosylceramide)
promotes cholesterol accumulation in macrophage foam
cells [14], inhibits cellular cholesterol removal via the
ABCA1 (ATP-binding cassette, subfamily A, member
1)/apoA-I (apolipoprotein A-I) pathway [15], induces
monocyte adhesion to endothelial cells [16] and
stimulates vascular smooth muscle cell proliferation [17].
This body of work suggests that sphingolipid synthesis
inhibition may be a feasible therapeutic target for the
treatment of atherosclerosis.
Several studies have shown that the SPT (serine
palmitoyltransferase) inhibitor myriocin is a potent
inhibitor of atherosclerosis in apoE−/− mice [18–22].
Myriocin inhibits the initial step in the sphingolipid
biosynthetic pathway, which could potentially result
in the modulation of several downstream sphingolipid
family members. Therefore, the precise mechanism(s) by
which myriocin exerts its potent anti-atherogenic action
is presently unknown. Myriocin may exert its effects
by reducing the concentrations of lipids downstream
of ceramide [such as SM, GSLs, C1P (ceramide 1phosphate) and S1P (sphingosine 1-phosphate)] or by
altering the expression of anti-atherogenic genes in the
liver. Findings from apoE−/− mouse studies indicate that
induction of hepatic apoA-I production is one plausible
anti-atherogenic action of myriocin [21,23].
It is widely reported that sphingolipids are critical
mediators of intracellular signalling pathways [24–26].
This has lead us to consider signalling pathways that could
potentially link the action of myriocin to the increased
hepatic apoA-I synthesis we observed in vivo [21]. It has
been reported that S1P stimulates the phosphorylation
of the MAPK (mitogen-activated protein kinase) ERK2

(extracellular-signal-related kinase 2) [27,28]. This activation of ERK2 is mediated by upstream kinases such as
MEK (MAPK/ERK kinase), MEK kinase and Raf-1. The
phosphorylation of ERK2 leads to dimer formation with
other ERK elements. Dimerization leads to translocation
to the nucleus where the ERK dimers phosphorylate
various transcription factors that can regulate gene
expression. Interestingly, it has been established that
basal and TNFα (tumour necrosis factor α)-mediated
suppression of apoA-I transcription is modulated via
an ERK pathway [29] and that myriocin reduces
intracellular S1P levels and ERK phosphorylation [30].
This raises the possibility that myriocin may induce
apoA-I transcription via down-regulation of ERK
phosphorylation. To investigate this possibility, in the
current studies, we treated HepG2 cells and primary
murine hepatocytes with myriocin or the MEK inhibitor
PD98059 and assessed the impact this has on hepatic ERK
phosphorylation and apoA-I production.

MATERIALS AND METHODS
Materials
Inhibitor compounds myriocin (cat. no. M1177) and
PD98059 (cat. no. P215) were obtained from Sigma.
The anaesthetic agent sodium pentobarbitone (cat.
no. 35976/01A) was obtained from Rhone Merieux.
Inhalation anaesthetic methoxyflurane (cat. no. 43144)
was from Medical Developments International. The
collagenase mixture Liberase Blendzyme 3 (cat. no.
11814176001) was obtained from Roche. All organic
solvents were of analytical grade and were purchased
from Ajax Finechem. All other reagents were purchased
through standard commercial suppliers.

Cell culture
HepG2 cells were grown under standard culture
conditions at 37 ◦ C in DMEM (Dulbecco’s modified
Eagle’s medium–low glucose, 1 mg/ml) supplemented
with 10 % FCS (fetal calf serum), 2 mM glutamine,
50 units/ml penicillin G and 50 μg/ml streptomycin
(Invitrogen) in a humidified atmosphere containing 5 %
CO2 . The cells were subcultivated by trypsinization at a
1:3 ratio and transferred to CellBIND® 12-well cluster
plates (cat. no. 3336; Corning) for use in experiments.
Primary mouse hepatocytes were isolated from livers
obtained from apoE−/− mice and cultured under identical
conditions. Cells were treated with myriocin or PD98059
as indicated for up to 48 h. These compounds were
added to cells in the absence of serum to enable accurate
quantification of secreted apoA-I in culture supernatants.

Myriocin administration and isolation of
murine hepatocytes
Male apoE−/− mice were supplied by the Animal
Resources Centre. Primary hepatocytes were isolated
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[31] from control mice and from mice that were injected
i.p. (intraperitoneally) with myriocin (0.3 or 1.0 mg/kg
of body weight) three times over 5 days (days 1, 3
and 5) as previously described [20]. Briefly, mice were
anaesthetized with sodium pentobarbitone (50 mg/kg of
body weight, i.p.) and methoxyflurane (inhalation), and
an incision was made down the ventral midline to reveal
the viscera. The organs were displaced to allow access
to the liver. A ligature was placed around the vena cava
upstream of the renal veins and tied off around a 24-gauge
catheter inserted into the vena cava downstream of the
ligature. A perfusion was initiated (50 ml of Krebs–Ringer
containing 20 mM glucose and 0.1 mM EGTA, pH 7.4) at
2 ml/min. The portal vein was then severed, and the flow
rate was increased to 7 ml/min. The anterior vena cava was
clamped between the diaphragm and heart using a small
haemostat. The perfusion was continued with a second
buffer (50 ml of Krebs–Ringer containing 20 mM glucose,
1.37 mM CaCl2 and 0.021 mg/ml Liberase Blendzyme 3,
pH 7.4). The liver was then excised into a Petri dish with
20 ml of chilled perfusion buffer and ruptured with a
scalpel. The cells were dispersed by aspiration through a
large-bore pipette and isolated by centrifugation at 100 g
for 5 min at 4 ◦ C. Cells were washed three times with icecold culture medium (DMEM). The cells were plated at a
density of 1.0×106 cells · ml−1 · well−1 . Hepatocytes that
were isolated from mice receiving myriocin were analysed
in experiments 2 h after plating down. Cell viability
exceeded 90 %, as assessed by Trypan Blue staining.
All precautions were taken to ensure that the animals
did not suffer unduly during and after the experimental
procedure. The work was undertaken with approval from
the University of New South Wales Animal Care and
Ethics Committee (Approval No. 08/38A).

SM analysis
Analysis of cell lysates for SM was based on a published
method [32]. SM measurement involved a four-step
enzymatic process, whereby SMase (sphingomyelinase)
(cat. no. S-7651; Sigma) hydrolysed SM to phosphorylcholine and N-acylsphingosine. Subsequently,
alkaline phosphatase (cat. no. P5521; Sigma) generated
choline from phosphorylcholine, which in turn was used
to generate H2 O2 in a reaction catalysed by choline
oxidase (cat. no. C5896; Sigma). The final step detected
liberated H2 O2 using DAOS [N-ethyl-N-(2-hydroxy3-sulfopropyl)-3,5-dimethoxyaniline sodium salt] (cat.
no. OC06; Dojindo Molecular Technologies), 4-AAP
(4-aminoantipyrine) (cat. no. A4382; Sigma) and HRP
(horseradish peroxidase) (cat. no. P1139; Sigma) to
generate a blue dye. The reaction buffer components
were prepared in 0.05 M Tris/HCl and 0.66 mM calcium
chloride, pH 8. Enzyme concentrations in a 10-ml reaction buffer were as follows: 5 units of SMase, 100 units
of alkaline phosphatase, 5 units of choline oxidase and
200 units of HRP. 4-AAP and DAOS concentrations
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were both 0.73 mM. Cell lysate (5 μl) was added to
100 μl of reaction buffer and, after 45 min of incubation
at 37 ◦ C, the absorption was measured at 595 nm using
a spectrophotometric plate reader (Model 550; Bio-Rad
Laboratories). A standard curve was prepared using
aliquots of a stock SM solution (1 mg/ml) prepared by
dissolving 10 mg of SM in 10 ml of 2 % (w/v) Triton
X-100 in ethanol.

Real-time qPCR (quantitative PCR)
analysis of HepG2 cell and primary
murine hepatocyte apoA-I mRNA
RNA was isolated from the cell monolayers using TRIzol® reagent (Invitrogen) according to the
manufacturer’s protocol. All procedures were carried
out using RNase-free reagents. RNA was reversetranscribed into cDNA using MMLV (Moloney-murineleukaemia virus) reverse transcriptase and random
primers (Promega). cDNA generated from the reverse
transcription of total RNA was used as a template in
the qPCR assay. qPCR amplification was carried out
using a Mastercycler ep realplex S (Eppendorf) and the
fluorescent dye SYBR Green (Eppendorf) according to
the manufacturer’s protocol. Briefly, each reaction (20 μl)
contained 20 pmol of primers, 1× Real MasterMix,
0.5× SYBR Green and 1 μl of template. Amplification
was carried out with 40 cycles of denaturation (94 ◦ C,
30 s), annealing (57 ◦ C, 30 s) and extension (72 ◦ C, 30 s).
All gene expressions were normalized to β-actin or
Gapdh (glyceraldehyde-3-phosphate dehydrogenase).
The primer sequences (5 –3 ) and PCR product sizes
are as follows: human apoA-I (234 bp) forward, CTTGGCCGTGCTCTTCCTGAC, and reverse, TTCCCGTTCTCAGCCTTGAC; human β-actin (162 bp) forward,
GAATTCTGGCCACGGCTGCTTCCAGCT, and reverse, AAGCTTTTTCGTGGATGCCACAGGACT;
mouse apoA-I (129 bp) forward, GGCACGTATGGCAGCAAGAT, and reverse, CCAAGGAGGAGGATTCAAACTG; mouse Gapdh (83 bp) forward, TGGTGAAGCAGGCATCTGAG, and reverse, TGCTGTTGAAGTCGCAGGAG.

Western blot analysis of HepG2 cells and
mouse primary hepatocytes
Cell monolayers were lysed in 400 μl of RIPA buffer
[20 mM Tris/HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA,
1 % Nonidet P40, 0.5 % deoxycholate, 0.1 % SDS
and protease inhibitors (cat. no. 11836153001; Roche)].
Culture supernatant samples were also collected. Lysate
(32 μl) was mixed with 8 μl of 5× Laemmli sample buffer
and 30 μl was routinely used for SDS/PAGE and Western
blotting. Culture supernatant (36 μl) was mixed with 9 μl
of 5× Laemmli sample buffer and 40 μl was loaded on to
gels. All samples were heated at 95 ◦ C for 5 min and briefly
centrifuged before loading. Samples were separated by
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SDS/PAGE (12 % gels) using a Bio-Rad Laboratories
mini-gel system. The proteins were transferred on to
0.45 μm Trans-Blot nitrocellulose membranes (cat. no.
162-0115; Bio-Rad Laboratories), and the membranes
were probed with a 1:2000-diluted rabbit anti-(human
apoA-I) polyclonal antibody that cross-reacts strongly
with mouse apoA-I (cat. no. 178422; Calbiochem)
and detected with 1:2000-diluted HRP-conjugated antirabbit secondary antibody (cat. no. 2012-09; DAKO) and
ECL (enhanced chemiluminescence) advanced detection
reagents (GE Healthcare). Membranes were also probed
with rabbit anti-ERK1/2 polyclonal (cat. no. 9102; Cell
Signaling Technology) or mouse anti-phospho-ERK1/2
polyclonal (cat. no. 442706; Calbiochem) antibodies, both
used at 1:2000 dilutions. Blots were also probed for
β-actin using rabbit anti-actin polyclonal antibodies (cat.
no. 057K4856; Sigma) to confirm equal protein loading.
The intensity of the protein bands was measured using
ImageJ software, which is available in the public domain
(http://rsb.info.nih.gov/ij/).

Cell viability assay
Primary mouse hepatocytes were seeded into 96well plates at 80 % confluency. Cells were treated
with the indicated doses of myriocin for 48 h.
The culture medium was removed, and 100 μl of
medium (DMEM and 10 % FCS) containing 0.5 mg/ml
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2Htetrazolium bromide] (cat. no. M2128; Sigma) was
added, and cells incubated for 3 h at 37 ◦ C. The medium
was discarded and cells were dissolved in DMSO
(100 μl/well), and the absorbance of the cell lysates was
measured at 550 nm. Higher absorbance values indicate
increased cell viability.

Statistics

All results are presented as means +
− S.E.M. of triplicate
or quadruplicate samples with experiments routinely
repeated three times. Statistical significance for differences in mRNA and protein levels was determined using
a Student’s t test. Differences were considered significant
at P < 0.05.

RESULTS
It has been shown previously that SPT inhibition can
reduce cellular S1P levels and ERK2 phosphorylation
[30]. In the current study, 100 and 200 μM myriocin
were applied to HepG2 cells and primary hepatocytes
for up to 48 h to determine its affect on apoA-I levels
and ERK phosphorylation. In HepG2 cells, myriocin
increased apoA-I mRNA levels 2.5-fold over controls
after 24 h. This was extended to a 3-fold increase after
48 h incubation (Figure 1A). This increase was also
reflected at the protein level, although the increase

was not as dramatic, with intracellular apoA-I protein
levels raised by 1.4-fold. ApoA-I secretion also increased
by 1.3-fold (Figures 1B and 1C). This was repeated
using 200 μM myriocin and the membrane probed
for total ERK and phospho-ERK, as well as apoA-I
(Figure 2). Once again, apoA-I protein levels were
increased ∼ 1.4-fold. ERK phosphorylation was reduced
by ∼ 50 %, with total ERK levels remaining unchanged.
This indicates that reduced phospho-ERK levels are not
due to reduced levels of total ERK. All protein levels
were normalized to β-actin. The impact of myriocin on
apoA-I mRNA levels was also analysed by qPCR, and a
2-fold increase was demonstrated (Figure 2B).
In order to use in vitro conditions that more closely
resemble the in vivo experiments in which myriocin
has been shown to potently inhibit atherosclerosis [20],
we focused on the study of primary hepatocytes. The
experiments using the HepG2 hepatocarcinoma cell
line were replicated using primary mouse hepatocytes
under identical conditions. Primary hepatocytes were
treated with 200 μM myriocin for 24 h. In a similar
fashion to HepG2 cells, myriocin increased apoA-I
protein levels 1.6-fold over controls. ApoA-I secretion
also increased 2.4-fold. Furthermore, myriocin increased
apoA-I mRNA levels ∼ 3-fold (Figure 3). This was
repeated in a separate series of experiments and the
membranes probed for total ERK, phospho-ERK, as well
as apoA-I. Cell supernatants were also assessed for apoAI secretion (Figure 4A). Cellular apoA-I protein levels
were increased 1.7-fold, with secreted apoA-I increasing
3.4-fold (Figure 4B). ERK phosphorylation was reduced
by 72 %, with total ERK and β-actin levels remaining
unchanged. Again, myriocin increased apoA-I mRNA
levels 2-fold (Figure 4B).
ERK activation is a rapidly inducible and dynamic
process. We therefore also assessed earlier time points
(<24 h) to examine if apoA-I expression can be rapidly
induced by 200 μM myriocin. The results indicate that
there was no induction of apoA-I mRNA after 1 h
(Figure 5A). A moderate (40 %) increase in apoA-I
mRNA was detected after 6 h, and strong induction
(2.3-fold) was observed at 24 h (Figure 5A). Although
a consistent significant myriocin-mediated induction of
cellular and secreted apoA-I protein levels was observed
by 24 h (as shown above), no consistent up-regulation
of apoA-I protein levels was detected at the 1 and 6 h
time points (results not shown). We did not detect any
significant changes in β-actin levels even at the highest
myrocin dose used (200 μM) after 48 h. In order to check
for possible cytotoxic/cytostatic properties that may be
associated with myriocin, an MTT reduction assay for cell
viability was also conducted using primary hepatocytes
treated with various doses of myriocin for 48 h. The
results indicate that there was a moderate (10 % to 19 %)
but statistically significant decrease in MTT reduction
in cells treated with either 100 or 200 μM myriocin
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Figure 2 Myriocin-mediated up-regulation of HepG2 cell
apoA-I production is associated with inhibition of ERK
phosphorylation

(A) HepG2 cells were treated with 200 μM myriocin for 24 h, and apoA-I, ERK,
phospho-ERK (pERK) and β-actin levels were analysed by Western blotting. (B)
Signal intensity of the bands quantified by Image-J software. Analysis of apoA-I
mRNA expression via qPCR was performed under identical conditions. Grey bars,
control; black bars, myriocin-treated. Results are means +
− S.E.M. **P < 0.01 as
assessed by Student’s t test.

Figure 1 Myriocin
production

up-regulates

HepG2

cell

apoA-I

(A) HepG2 cells were treated with 100 or 200 μM myriocin for 24 or 48 h, and
mRNA expression was assessed by qPCR. (B and C) HepG2 cells were treated with
100 or 200 μM myriocin for 24 h. The cell medium was collected after 24 h,
and apoA-I expression and secretion were analysed by Western blotting. Signal
intensity of the apoA-I bands was quantified using Image-J software and the
results are expressed relative to controls. Results are means +
− S.E.M. *P < 0.05,
**P < 0.01 and ***P < 0.0001 as assessed by Student’s t test.

for 48 h (Figure 5B). This indicates that, although
myriocin does appear to have a moderate impact on
cellular MTT reduction, viability remained high, and the
myriocin-mediated induction of hepatocyte apoA-I is not
likely to be due to non-specific cytotoxic effects of the
drug.
The extent of myriocin-mediated inhibition of SPT
activity in both HepG2 cells and primary murine
hepatocytes was confirmed by measurement of SM levels

in cell lysates. The results indicated that 24 h treatment
with 200 μM myriocin reduced HepG2 cell and primary
hepatocyte SM levels by 47 % and 38 % respectively
(Figure 6). The extent of SM depletion observed in these
in vitro experiments is similar to the reductions achieved
in our previous in vivo studies. When apoE−/− mice
were treated with myriocin by either i.p. injection or oral
administration, decreases in plasma SM of 42 % and 54 %
respectively, were achieved [20,21]. Of more relevance
to the hepatocyte, chronic administration of myriocin
to apoE−/− mice reduced hepatic SM levels by (39 %)
[20,21].
We next examined whether myriocin could induce
apoA-I expression and inhibit ERK activation in
hepatocytes isolated from mice that were acutely treated
with myriocin. In this experiment, mice were injected
i.p. with myriocin three times at either 0.3 or 1.0 mg/kg
of body weight over 5 days (i.e. injected on days 1,
3 and 5). Approximately 2 h after the final injection,
hepatocytes were isolated and plated out as described
in the Materials and methods section. At 2 h after plating,
the cells were harvested and assessed for apoA-I and
ERK/phospho-ERK expression (secreted apoA-I protein
levels could not be reliably quantified by Western blotting
in the medium taken from freshly isolated hepatocytes
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Figure 3 Myriocin up-regulates mouse hepatocyte apoA-I
production

(A) Primary hepatocytes were treated with 200 μM myriocin for 24 h. ApoA-I
and β-actin levels were analysed by Western blotting. (B) Signal intensity of the
bands was quantified using Image-J software. Analysis of apoA-I mRNA expression
via qPCR was performed under identical conditions. Grey bars, control; black bars,
myriocin-treated. Results are means +
− S.E.M. *P < 0.05 and ***P < 0.0001 as
assessed by Student’s t test. cell, cellular, sec, secreted.

that were plated down for only 2 h; results not shown).
Hepatocytes derived from mice treated with myriocin
at a dose of 0.3 mg/kg of body weight had 1.72- and
1.92-fold increased levels of apoA-I protein and mRNA
respectively, compared with PBS-injected control mice
(Figure 7). Interestingly, there was no further induction of
hepatocyte apoA-I in animals treated with the higher dose
(1 mg/kg of body weight) of myriocin. We also detected
a moderate 25 % inhibition of hepatocyte phosphoERK in the myriocin-treated mice (Figure 7). These
results indicate that the association of myriocin-mediated
stimulation of apoA-I synthesis with decreased ERK
activation is relevant to both the in vitro and in vivo
experimental settings.
The myriocin-mediated inhibition of hepatocyte ERK
phosphorylation we identified suggests that modulation
of the ERK pathway may be directly involved in the upregulation of hepatic apoA-I synthesis. However, it is
also possible that the inhibition of ERK phosphorylation
by myriocin is merely coincidental with up-regulated
apoA-I production. To further understand the link
between apoA-I transcription and ERK phosphorylation, we treated mouse hepatocytes with 50 μM
PD98059. PD98059 is a potent inhibitor of MEK,
the kinase that activates ERK. The cell lysates and
supernatants were collected and analysed by SDS/PAGE

Figure 4 Myriocin-mediated up-regulation of mouse
hepatocyte apoA-I is associated with inhibition of
ERK phosphorylation

(A) Primary mouse hepatocytes were treated with 200 μM myriocin for 24 h. The
medium was collected after 24 h. Cellular apoA-I (cell) ERK, phospho-ERK (pERK)
and β-actin and secreted apoA-I (sec) levels were analysed by Western blotting.
(B) Signal intensity of the bands quantified using Image-J. Analysis of apoA-I
mRNA expression via qPCR was performed under identical conditions. Grey bars,
control; black bars, myriocin-treated. Results are means +
− S.E.M. **P < 0.01 and
***P < 0.0001 as assessed by Student’s t test.

and Western blotting as above. ERK phosphorylation
was reduced by 89 %, with total ERK and β-actin levels
remaining unchanged (Figure 8A). Cellular and secreted
apoA-I protein levels were increased 1.3- and 3.3-fold
respectively (Figure 8A). A modest but statistically
significant increase in apoA-I mRNA level was also
detected (Figure 8B). This adds further support to our
proposal that myriocin-mediated inhibition of ERK
phosphorylation plays a role in the up-regulation of
hepatocyte apoA-I production.

DISCUSSION
We have previously shown that the SPT inhibitor
myriocin significantly inhibits atherosclerosis in
apoE−/− mice [20,21]. As predicted, this was associated
with significant reductions in plasma SM concentrations.
We also reported that the anti-atherogenic activity of
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Figure 5 Time course study of myriocin-mediated up-regulation of mouse hepatocyte apoA-I mRNA and its impact on
cell viability

(A) Primary mouse hepatocytes were treated with 200 μM myriocin for 0 to
24 h. Cells were extracted in TRIzol® reagent, and apoA-I mRNA expression was
assessed by qPCR. (B) Primary mouse hepatocytes were treated with 200 μM
myriocin 48 h and cell viability assessed using the MTT reduction assay. Grey bars,
control; black bars, myriocin-treated. Results are means +
− S.E.M. **P < 0.01 and
***P < 0.0001 as assessed by Student’s t test.

Figure 6 Myriocin decreases SM levels in mouse hepatocytes and HepG2 cells

Cell lysate (5 μl) was added to a 95-μl reaction buffer (see Materials
and methods section for details) and, after 45 min of incubation at 37 ◦ C,
the absorbance was measured at 595 nm using a spectrophotometric plate
reader. The absolute value for total SM, represented by the 100 % relative SM,
amount for hepatocytes, was 1.20 +
− 0.02 nmol/mg of cell protein. Grey bars,
control; black bars, myriocin-treated. Results are means +
− S.E.M. **P < 0.01 and
***P < 0.0001 as assessed by Student’s t test.
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Figure 7 Analysis of apoA-I and ERK levels in hepatocytes
derived from myriocin-treated mice

(A) ApoE−/− mice were injected i.p. with myriocin at 0.3 or 1 mg/kg of body
weight or PBS as a vehicle control, as described in the Materials and methods
section. The animals were killed, and primary hepatocytes were isolated and
assessed for apoA-I, ERK, phospho-ERK (pERK) and β-actin by Western blotting.
(B) Signal intensity of the bands was quantified by Image-J software and analysis
of apoA-I mRNA expression via qPCR was performed under identical conditions.
White bars, control; grey bars, 0.3 mg/kg myriocin-treated; black bars, 1 mg/kg
myriocin-treated. Results are means +
− S.E.M. of three mice in each treatment
group. *P < 0.05 and **P < 0.01 as assessed by Student’s t test.
myriocin was associated with a 29 % reduction in plasma
GSL levels [20]. The fact that SPT inhibition may have an
impact on numerous members of the sphingolipid family,
which could theoretically regulate lesion development
[7], led us to examine the selective inhibition of GCS
(glucosylceramide synthase, which catalyses the initial
step in GSL biosynthesis) as a potential modulator of
atherosclerosis in apoE−/− mice. In the latter study,
we employed the GSL synthesis inhibitor EtDO-P4
(d-threo-1-ethylendioxyphenyl-2-palmitoylamino-3-pyrrolidino-propanol), and observed that over a 4month period on a high-fat/high-cholesterol diet, a
49 % reduction in plasma GSL levels (P < 0.0001)
was achieved by drug administration. However, this
was not associated with a significant reduction in
atherosclerosis [33,34]. Interestingly, a recent report
suggests that another GCS inhibitor, N-(5-adamantane1-yl-methoxy-pentyl)-deoxynojirimycin, significantly
reduces atherosclerosis in the APOE*3 Leiden mouse
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Figure 8 Inhibition of ERK phosphorylation up-regulates
mouse hepatocyte apoA-I production

(A) Primary hepatocytes were treated with 50 μM PD98059 for 24 h. The
medium was collected after 24 h. Cellular apoA-I (cell), ERK, phospho-ERK (pERK)
and β-actin and secreted apoA-I (sec) levels were analysed by Western blotting.
(B) Signal intensity of the bands was quantified by Image-J software. Analysis of
apoA-I mRNA expression via qPCR was performed under identical conditions. Grey
bars, control; black bars, myriocin-treated. Results are means +
− S.E.M. *P < 0.05,
**P < 0.01 and ***P < 0.0001 as assessed by Student’s t test.
model of atherosclerosis [35]. Therefore, it remains
possible that myriocin-mediated inhibition of GSL
synthesis does contribute to its anti-atherogenic activity
[20].
Regardless of the impact on GSL synthesis, myriocin
also increases hepatic and plasma apoA-I levels by
45 % and 38 % respectively, in apoE−/− mice [21]. This
has also been previously reported in a study showing that
apoE−/− mice treated with myriocin at a concentration
of 1 mg−1 · kg−1 of body weight · day−1 by oral
gavage for 5 days increased hepatic apoA-I mRNA
expression by 30 % [23]. Since raising plasma apoAI levels by pharmacological means has been a major
research focus for some time [36], our current objective
was to gain information on the underlying mechanism(s)
by which myriocin may induce apoA-I expression. This
information was also sought in order to help explain its
anti-atherogenic actions in vivo.
Myriocin reduces plasma S1P concentration in
association with inhibition of atherosclerosis in apoE−/−

mice [19]. Given that S1P has been shown to stimulate
ERK phosphorylation, and that ERK activation has been
implicated in the suppression of apoA-I transcription
[29,30], we hypothesized that myriocin may induce
hepatic apoA-I synthesis through an inhibition of the
ERK signalling pathway. Our findings clearly support
this hypothesis by showing that myriocin significantly
raises apoA-I mRNA and protein levels in both HepG2
cells and primary mouse hepatocytes in association with
an inhibition of ERK phosphorylation. Furthermore, we
observed a similar up-regulation of apoA-I synthesis and
suppression of ERK activation in hepatocytes derived
from mice that were treated with myriocin. The role of
suppressed ERK signalling in the mechanisms underlying
myriocin-mediated up-regulation of hepatic apoA-I
production is also supported by our results showing
that selective inhibition of ERK phosphorylation with
PD98059 significantly increased apoA-I mRNA and
protein levels in primary hepatocytes. Importantly, this
was associated with a significant increase in hepatocyte
apoA-I secretion as well.
The question now arises as to the therapeutic relevance
of these observations. As far as we are aware, selective
targeting of hepatic ERK phosphorylation has not been
previously studied as means to increase plasma apoA-I
or HDL (high-density lipoprotein) levels in humans.
However, there is one clinical scenario that may have
a bearing on our current findings. It is recognized that
patients treated with the antipsychotic dibenzodiazepines
olanzapine and the closely related clozapine can develop
a dyslipidaemia that is characterized by increased total
plasma cholesterol and triacylglycerol (triglyceride) levels
and decreased HDL-cholesterol and apoA-I levels [37–
39]. Intriguingly, clozapine was recently shown to
stimulate ERK phosphorylation [40], an event that we
would speculate could result in suppression of hepatic
apoA-I synthesis. Whether a compound such as myriocin
could be utilized to ameliorate the unwanted side effects
that dibenzodiazepines have on plasma HDL-cholesterol
levels remains to be examined. It is important to note that
the influence of dibenzodiazepines on weight gain may
also independently result in lowered HDL-colesterol
levels, and it would therefore be premature to ascribe
antipsychotic drug-induced changes in hepatic ERK
activation as the cause of lowered HDL-C in human
patients.
Other studies in humans have examined the immunosuppressive function of a myriocin-based drug FTY720
[41]. FTY720 is an S1P homologue that, after in vivo
phosphorylation, acts as an agonist of G-protein-coupled
sphingolipid receptors. Previous studies in LDLr (LDL
receptor)−/− mice and apoE−/− mice have shown that
FTY720 inhibits atherosclerosis in both these animal
models; however, the anti-atherogenic action of FTY720
was not associated with increased HDL levels [42,43].
Consistent with this, we found that FTY720 did not alter
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hepatocyte apoA-I synthesis (E. Glaros and B. Garner,
unpublished work). The anti-atherogenic mechanisms of
action for myriocin and FTY720 therefore appear to
be quite distinct. Previous studies have indicated that
myriocin may regulate the synthesis of multiple classes
of sphingolipids including ceramides and GSLs [7].
Although we have shown that selective GSL inhibition
does not affect overall plasma lipid profiles in apoE−/−
mice [34], we cannot rule out a possible role for altered
levels of GSLs, ceramides or other sphingolipid species as
contributing to the pathways by which myriocin induces
hepatic apoA-I synthesis.
In conclusion, our results extend existing current
knowledge in the area of sphingolipid inhibitors for the
treatment of atherosclerosis by demonstrating that an
up-regulation of hepatic apoA-I synthesis by myriocin
is associated with inhibition of ERK phosphorylation.
Identification of specific therapeutic targets in the
sphingolipid biosynthetic pathway could lead to novel
approaches that may be used in isolation or in conjunction
with cholesterol-lowering therapies to better treat
atherosclerosis.
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